Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
 <li>
Market Leader in Structural Heart: <a href="https://smartkarma.com/entities/edwards-lifesciences-corp-3d2d3c64-eacd-4c74-9289-e38e85bd816b">Edwards Lifesciences </a>is a global leader in the structural heart device market, particularly in Transcatheter Aortic Valve Replacement (TAVR), a minimally invasive procedure that has become a standard of care. Its flagship SAPIEN valve platform is a primary revenue driver.</li>
 <li>
Strong Growth in Emerging Therapies: The company is experiencing rapid growth in its Transcatheter Mitral and Tricuspid Therapies (TMTT) segment, which is expected to be a significant contributor to future growth, diversifying revenues away from the more mature TAVR market.</li>
 <li>
Focused Strategy and Innovation Pipeline: Following the planned spin-off of its Critical Care business, Edwards will be a pure-play structural heart company. A robust R&amp;D pipeline, with significant investment in next-generation TAVR, TMTT, and other emerging technologies, positions the company for sustained long-term growth.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  
Market Leader in Structural Heart: Edwards Lifesciences is a global leader in the structural heart device market, particularly in Transcatheter Aortic Valve Replacement (TAVR), a minimally invasive procedure that has become a standard of care. Its flagship SAPIEN valve platform is a primary revenue driver.
  
Strong Growth in Emerging Therapies: The company is experiencing rapid growth in its Transcatheter Mitral and Tricuspid Therapies (TMTT) segment, which is expected to be a significant contributor to future growth, diversifying revenues away from the more mature TAVR market.
  
Focused Strategy and Innovation Pipeline: Following the planned spin-off of its Critical Care business, Edwards will be a pure-play structural heart company. A robust R&amp;D pipeline, with significant investment in next-generation TAVR, TMTT, and other emerging technologies, positions the company for sustained long-term growth.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Edwards Lifesciences  (EW UN) - Sep 2025

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

<ul><li>Edwards Lifesciences has reported its financial results for the second quarter of 2025, demonstrating a robust performance across various segments.</li><li>The company, which specializes in heart valve technologies and structural heart therapies, showcased a notable double-digit sales growth, driven by the dynamic expansion of its Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) product lines.</li><li>Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.</li></ul>

Edwards Lifesciences has reported its financial results for the second quarter of 2025, demonstrating a robust performance across various segments.The company, which specializes in heart valve technologies and structural heart therapies, showcased a notable double-digit sales growth, driven by the dynamic expansion of its Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) product lines.Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

Edwards Lifesciences: Will Its Focus On New & Potentially Game-Changing Heart Therapies Pay Off?

<ul><li>Edwards Lifesciences Corporation reported a solid performance for the first quarter of 2025, with total company sales reaching $1.41 billion, which indicates an 8% growth.</li><li>This growth reflects the company's continued commitment to innovation in the field of structural heart disease, bolstered by its diverse product portfolio.</li><li>The Transcatheter Aortic Valve Replacement (TAVR) segment, with sales of $1.05 billion, experienced growth of 5.4% year-over-year.</li></ul>

Edwards Lifesciences Corporation reported a solid performance for the first quarter of 2025, with total company sales reaching $1.41 billion, which indicates an 8% growth.This growth reflects the company's continued commitment to innovation in the field of structural heart disease, bolstered by its diverse product portfolio.The Transcatheter Aortic Valve Replacement (TAVR) segment, with sales of $1.05 billion, experienced growth of 5.4% year-over-year.

How Edwards Lifesciences Is Breaking Barriers in Valve Replacement with M3 & EVOQUE!

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>
<a href="https://www.smartkarma.com/entities/medtronic-plc" target="_blank" data-smartkarma-citation="entities:14982:1" rel="noopener">Medtronic Plc (MDT US)</a> has submitted the Hugo robotic-assisted surgery system to the FDA for a urologic indication in 1Q25. In clinical trial, Hugo met the safety and effectiveness endpoints.</li>
<li>Approval is expected in 2H25. Medtronic expects Hugo would contribute to the company’s surgical business in FY26 and will be ‘a meaningful growth driver’ for the company in the medium-term.</li>
<li>Medtronic is well-positioned for accelerated growth, driven by momentum in some of the most attractive growth markets in MedTech. The U.S. approval of Hugo is an icing on the cake.</li>
</ul>



Medtronic Plc (MDT US) has submitted the Hugo robotic-assisted surgery system to the FDA for a urologic indication in 1Q25. In clinical trial, Hugo met the safety and effectiveness endpoints.
Approval is expected in 2H25. Medtronic expects Hugo would contribute to the company’s surgical business in FY26 and will be ‘a meaningful growth driver’ for the company in the medium-term.
Medtronic is well-positioned for accelerated growth, driven by momentum in some of the most attractive growth markets in MedTech. The U.S. approval of Hugo is an icing on the cake.


Medtronic Plc (MDT US): New Approvals to Accelerate Growth Ahead; A Good Time to Buy

<ul><li>Edwards Lifesciences Corporation recently reported its financial results for the fourth quarter and the full year of 2024, providing an insight into its strategic performance and outlook.</li><li>The company, solely focused on structural heart solutions after divesting its Critical Care segment in the third quarter of 2024, recorded robust financial performance, consistent with its expectations and strategic focus.</li><li>For the full year 2024, Edwards Lifesciences reported a 9% increase in sales, reaching $5.4 billion.</li></ul>

Edwards Lifesciences Corporation recently reported its financial results for the fourth quarter and the full year of 2024, providing an insight into its strategic performance and outlook.The company, solely focused on structural heart solutions after divesting its Critical Care segment in the third quarter of 2024, recorded robust financial performance, consistent with its expectations and strategic focus.For the full year 2024, Edwards Lifesciences reported a 9% increase in sales, reaching $5.4 billion.

Edwards Lifesciences: Inside the High-Stakes Race for the Next Big Cardiac Breakthrough!

United States

Edwards Lifesciences Corporation designs, develops, manufactures, and markets products and services to treat late-stage cardiovascular disease.  The Company's products include tissue replacement heart valves, heart valve repair products, hemodynamic monitoring devices, angioscopy equipment, oxygenators, and pharmaceuticals.  Edwards supplies its products to customers located worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Edwards Lifesciences (EW US)

Primer: Edwards Lifesciences (EW UN) - Sep 2025

Market Leader in Structural Heart: Edwards Lifesciences is a global leader in the structural heart device market, particularly in Transcatheter...

αSK Primers

Edwards Lifesciences: Will Its Focus On New & Potentially Game-Changing Heart Therapies Pay Off?

Edwards Lifesciences has reported its financial results for the second quarter of 2025, demonstrating a robust performance across various...

Baptista Research

How Edwards Lifesciences Is Breaking Barriers in Valve Replacement with M3 & EVOQUE!

Edwards Lifesciences Corporation reported a solid performance for the first quarter of 2025, with total company sales reaching $1.41 billion,...

Baptista Research

Medtronic Plc (MDT US): New Approvals to Accelerate Growth Ahead; A Good Time to Buy

Medtronic submits Hugo robotic-assisted surgery system to FDA for urologic indication, with expected approval in 2H25. Hugo is poised to be a...

Tina Banerjee

Edwards Lifesciences: Inside the High-Stakes Race for the Next Big Cardiac Breakthrough!

Edwards Lifesciences Corporation recently reported its financial results for the fourth quarter and the full year of 2024, providing an insight...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Primer: Edwards Lifesciences (EW UN) - Sep 2025

Market Leader in Structural Heart: Edwards Lifesciences is a global leader in the structural heart device market, particularly in Transcatheter...

αSK Primers

Edwards Lifesciences: Will Its Focus On New & Potentially Game-Changing Heart Therapies Pay Off?

Edwards Lifesciences has reported its financial results for the second quarter of 2025, demonstrating a robust performance across various...

Baptista Research

How Edwards Lifesciences Is Breaking Barriers in Valve Replacement with M3 & EVOQUE!

Edwards Lifesciences Corporation reported a solid performance for the first quarter of 2025, with total company sales reaching $1.41 billion,...

Baptista Research

Medtronic Plc (MDT US): New Approvals to Accelerate Growth Ahead; A Good Time to Buy

​Medtronic submits Hugo robotic-assisted surgery system to FDA for urologic indication, with expected approval in 2H25. Hugo is poised to be a...

Tina Banerjee

Edwards Lifesciences: Inside the High-Stakes Race for the Next Big Cardiac Breakthrough!

Edwards Lifesciences Corporation recently reported its financial results for the fourth quarter and the full year of 2024, providing an insight...

Baptista Research

Medtronic submits Hugo robotic-assisted surgery system to FDA for urologic indication, with expected approval in 2H25. Hugo is poised to be a...